KRAS and non-small cell lung carcinoma: KRAS protein, other downstream effectors of EGFR such as serine-threonine kinase BRAF, and another member of the human epidermal growth factor receptor (HER) family, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 (HER-2), are also implicated in the tumorigenesis and progression of NSCLC [8, 9].